Dual-mode US/MRI nanoparticles delivering siRNA and Pt(<scp>iv</scp>) for ovarian cancer treatment

Zhang, Yanhua; Huang, Hui; Fu, Hao; Zhao, Meng; Wu, Zhihua; Dong, Yang; Li, He; Duan, Yourong; Sun, Ying

doi:10.1039/c9ra03681d

Cited by 4 publications

(3 citation statements)

References 27 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, in recent years several examples of nanoparticles have been proposed for simultaneous visualization using different diagnostic techniques. [96][97][98] However, research on novel supramolecular systems such as bers, hydrogels and nanogels has become particularly relevant aer the European Medicines Agency (EMA) decided to withdraw contrast agents based on linear chelators from the market as they were considered to not be sufficiently stable in relation to the in vivo release of toxic Gd(III) ions. Supramolecular systems have been identied as innovative vehicles for CAs that are able to signicantly increase their relaxivity values.…”

Section: Resultsmentioning

confidence: 99%

Systematic overview of soft materials as a novel frontier for MRI contrast agents

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic overview of soft materials as a novel frontier for MRI contrast agents

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This non-invasive imaging method requires USI contrast agents and phase transformation capacity by utilization of perfluorohexane (PFH) and an ultrasound therapeutic apparatus. [185][186][187][188] The DDSs encapsulated USI contrast agents could easily respond to ultrasound exposure for USI and Pt drug release. For example, Luo et al fabricated a PLGA vesicle for the encapsulation of Fe 3 O 4 , PFH, and cisplatin.…”

Section: Usi-guided Cancer Treatmentmentioning

confidence: 99%

Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy

Liu

Wang

et al. 2023

Small

View full text Add to dashboard Cite

made great progress in the field of medicinal inorganic chemistry. [2] They have been extensively applied in various types of cancers such as bladder cancer, ovarian cancer, breast cancer, endometrial cancer, neck cancer, and lung cancer. [3] Generally, Pt-based anticancer drugs interact with gene nucleobases and cause DNA damage. For example, after cellular uptake, cisplatin will hydrolyze along with the dissociation of chloride ion, which is ascribed to relatively lower concentration of chloride ion in cytoplasm (4-10 mm) than that in blood (≈100 mm). The hydrolyzed cisplatin can further conjugate with N7 position of adenine (A) and guanine (G), distort the structure of DNA and inhibit G2/M transition of cell cycle, leading to cell apoptosis in the end. [4][5][6] However, Pt(II) analogue drugs face various side effects, such as vomiting, neurotoxicity, nephrotoxicity, ototoxity, and cardiotoxicity. [7] These severe side effects greatly limit their efficacy and have become huge obstacles for further clinical applications. Though great efforts have been devoted to improve the efficacy of Pt-based anticancer drugs. Up to now, there is no Pt(II)-based drug that fully solves the problems despite of years of research. [8,9] Meanwhile, drug resistance is another major challenge for Pt-based drugs. Further, the anticancer efficacy of these Pt(II)-based drugs is greatly compromised by the inactivation of intracellular coppertransporting proteins, such as glutathione (GSH) and metallothioneins (MT), through forming stable Pt(II)-S bond. Later, copper transporter ATP7A and ATP7B are involved in the efflux or translocation Pt(II)-S complex as well as multidrug resistance-associated protein MRP2. What's more, it is noteworthy that DNA damage caused by Pt lesions can be recovered by the nucleotide excision repair (NER) machinery, in which DNAadduct repair enzymes play the critical role, such as excision repair cross complementation 1. [10,11] To minimize side effects of Pt(II) drugs, Pt(IV) prodrug have drawn more and more attention for cancer therapy. [12][13][14][15][16] Compared to Pt(II) drugs, these Pt(IV) drugs have a six coordinate octahedral geometry with an inert d 6 electronic configuration. The two additional ligands can endow Pt(IV) prodrugs with additional lipophilicity, tumor targeting property, and enhanced cellular uptake. [17] After endocytosis, these Pt(IV) drugs can be reduced to active Pt(II) drugs by intracellular GSH, resulting in enhanced therapeutic efficacy and reduced side effects. [18] Ideally, Pt drugs should kill cancer cells exclusively without damaging the normal ones. However, the tumor selectivity of Platinum (Pt) drugs are widely used in clinic for cancer therapy, but their therapeutic outcomes are significantly compromised by severe side effects and acquired drug resistance. With the emerging immunotherapy and imaging-guided cancer therapy, precise delivery and release of Pt drugs have drawn great attention these days. The targeting delivery of Pt drugs can greatly increase the accumulation...

show abstract

“…Of various multimodal imaging modalities, MR-based imaging systems, such as FL/MR, US/MR, CT/MR, and PET/MR, have received intensive interest in the design of promising theranostic nanoparticles, because MR imaging plays a role as a pivotal imaging modality due to its strength including no limitation in tissue-penetrating depth and the acquisition of images with a high spatial resolution [10][11][12][13][14]. Among the various MR-based theranostic platforms, the nanoparticles exhibiting FL/MR dual imaging functions are one of the most important research targets due to the complementary synergy of FL and MR imaging.…”

Section: Ivyspring International Publishermentioning

confidence: 99%

MnCO₃-mineralized polydopamine nanoparticles as an activatable theranostic agent for dual-modality imaging-guided photothermal therapy of cancers

Lee¹,

Lee²,

Lee³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Background: Single imaging modality is still insufficient to evaluate the biological and anatomical structures of tumors with high accuracy and reliability. Generation of non-specific contrast, leading to a low target-to-background signal ratio, results in low imaging resolution and accuracy. Tumor environment-specific activatable multifunctional contrast agents need to maximize the contrast signals, representing a dual imaging-guided photothermal therapy (PTT) at target tumor sites. Methods: Cellular uptake, cytotoxicity assay, and in vitro photothermal conversion efficiency of MnCO3-mineralized fluorescent polydopamine nanoparticles (MnCO3-FPNPs) were evaluated using 4T1 breast cancer cells. In vivo dual-modality imaging was performed using IVIS imaging and a 4.7 T animal MRI systems after injection into 4T1 tumor-bearing nude mice. The effects of photothermal therapeutic through PTT were measured after irradiation with an 808 nm laser (1.5 W/cm 2 ) for 10 min, measuring the size of the tumors every 2 days. Results: At physiological pH (7.4), MnCO3-FPNP is efficiently quenched. Conversely, at acidic pH (5.4), the strong fluorescence (FL) is recovered due to the dissociation of Mn 2+ from the FPNPs. At pH 7.4, MnCO3-FPNP activity is silenced to enhance water proton relaxation due to unionized MnCO3 maintenance; conversely, at acidic pH (5.4), MnCO3-FPNPs efficiently release Mn 2+ ions, thereby resulting in T1-weighted magnetic resonance (MR) contrast enhancement. MnCO3-FPNPs display a promising diagnostic ability for 4T1 breast cancer xenograft models, as well as exhibit a high photothermal conversion efficiency. A successful tumor treatment via their photothermal activity is accomplished within 14 days. Conclusions: Our studies exhibited unique "OFF-ON" activation abilities in FL/MR dual imaging and PTT functions. This approach suggests that the MnCO3-FPNPs may serve as a useful platform for various mineralization-based multimodal imaging-guided PTT models for many cancer theranostic applications.

show abstract

Dual-mode US/MRI nanoparticles delivering siRNA and Pt(iv) for ovarian cancer treatment

Abstract: Phase-shifted dual-mode US/MRI nanoparticles (PFH/siRNA/Fe3O4@Pt(iv) NPs-cRGD) delivering si-survivin and Pt(iv) prodrug for enhancing ovarian cancer treatment and realizing real-time monitoring.

Cited by 4 publications

References 27 publications

Systematic overview of soft materials as a novel frontier for MRI contrast agents

Systematic overview of soft materials as a novel frontier for MRI contrast agents

Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy

MnCO₃-mineralized polydopamine nanoparticles as an activatable theranostic agent for dual-modality imaging-guided photothermal therapy of cancers

Contact Info

Product

Resources

About

Dual-mode US/MRI nanoparticles delivering siRNA and Pt(iv) for ovarian cancer treatment

Abstract: Phase-shifted dual-mode US/MRI nanoparticles (PFH/siRNA/Fe3O4@Pt(iv) NPs-cRGD) delivering si-survivin and Pt(iv) prodrug for enhancing ovarian cancer treatment and realizing real-time monitoring.

Cited by 4 publications

References 27 publications

Systematic overview of soft materials as a novel frontier for MRI contrast agents

Systematic overview of soft materials as a novel frontier for MRI contrast agents

Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy

MnCO3-mineralized polydopamine nanoparticles as an activatable theranostic agent for dual-modality imaging-guided photothermal therapy of cancers

Contact Info

Product

Resources

About

MnCO₃-mineralized polydopamine nanoparticles as an activatable theranostic agent for dual-modality imaging-guided photothermal therapy of cancers